Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Buy rating and $23.00 price target

Analyst Ratings For Aridis Pharmaceuticals Inc (NASDAQ:ARDS)

Story continues below

Today, Laidlaw initiated coverage on Aridis Pharmaceuticals Inc (NASDAQ:ARDS) with a Buy with a price target of $23.00.

There are 2 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Aridis Pharmaceuticals Inc (NASDAQ:ARDS) is Buy with a consensus target price of $24.00 per share, a potential 98.02% upside.

Some recent analyst ratings include

  • 9/10/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Buy rating and $23.00 price target
  • 9/10/2018-Aridis Pharmaceuticals Inc (NASDAQ:ARDS) has coverage initiated with a Overweight rating


    Recent Trading Activity for Aridis Pharmaceuticals Inc (NASDAQ:ARDS)
    Shares of Aridis Pharmaceuticals Inc closed the previous trading session at 12.12 −1.18 8.87% with 13.46 shares trading hands.

    An ad to help with our costs